瑞莫拉宁、选定的糖肽类、氟喹诺酮类及其他抗生素对革兰氏阳性球菌临床血流分离株的体外活性。
In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.
作者信息
Lawrence T, Rotstein C, Beam T R, Gorzynski E A, Amsterdam D
机构信息
Department of Medical Technology, School of Medicine, State University of New York, Buffalo 14214.
出版信息
Antimicrob Agents Chemother. 1993 Apr;37(4):896-900. doi: 10.1128/AAC.37.4.896.
Abstract
The susceptibilities of 316 gram-positive bacteremic isolates to ramoplanin, vancomycin, and teicoplanin and seven other antibiotics were tested. Ramoplanin demonstrated MICs of < or = 0.25 microgram/ml for at least 99% of Staphylococcus aureus isolates and 100% of coagulase-negative staphylococci tested. For both oxacillin-susceptible and oxacillin-resistant S. aureus and coagulase-negative staphylococci, the activity of ramoplanin surpassed those of both vancomycin and teicoplanin. Ramoplanin and teicoplanin had comparable activities against enterococci and Streptococcus pneumoniae and were superior to vancomycin.
摘要
对316株革兰氏阳性菌血症分离株进行了瑞莫拉宁、万古霉素、替考拉宁及其他七种抗生素的药敏试验。瑞莫拉宁对至少99%的金黄色葡萄球菌分离株和100%的凝固酶阴性葡萄球菌的最低抑菌浓度（MIC）≤0.25微克/毫升。对于对苯唑西林敏感和耐药的金黄色葡萄球菌及凝固酶阴性葡萄球菌，瑞莫拉宁的活性均超过万古霉素和替考拉宁。瑞莫拉宁和替考拉宁对肠球菌和肺炎链球菌的活性相当，且优于万古霉素。
相似文献
1
In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.瑞莫拉宁、选定的糖肽类、氟喹诺酮类及其他抗生素对革兰氏阳性球菌临床血流分离株的体外活性。
Antimicrob Agents Chemother. 1993 Apr;37(4):896-900. doi: 10.1128/AAC.37.4.896.
2
In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.瑞莫拉宁（一种新型脂糖肽）、万古霉素和替考拉宁对癌症患者革兰氏阳性临床分离株的体外活性。
J Antimicrob Chemother. 1996 Aug;38(2):265-9. doi: 10.1093/jac/38.2.265.
3
Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.替考拉宁、达托霉素、雷莫拉宁、万古霉素和PD127,391对革兰氏阳性球菌血液分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jul;36(7):1570-2. doi: 10.1128/AAC.36.7.1570.
4
In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.万古霉素、替考拉宁、达托霉素、雷莫拉宁、MDL 62873及其他药物对葡萄球菌、肠球菌和艰难梭菌的体外活性。
J Antimicrob Chemother. 1990 Nov;26(5):627-33. doi: 10.1093/jac/26.5.627.
5
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).亚太地区革兰氏阳性菌分离株的抗菌药敏性以及达托霉素、万古霉素和替考拉宁杀菌活性的体外评估：哨兵计划报告（2003 - 2004年）
Int J Antimicrob Agents. 2007 Aug;30(2):143-9. doi: 10.1016/j.ijantimicag.2007.03.015. Epub 2007 May 24.
6
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.司帕沙星、环丙沙星、氧氟沙星及其他抗生素对革兰氏阳性球菌血流感染分离株的体外活性
Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k.
7
Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.台湾地区达托霉素、糖肽类、利奈唑胺和替加环素对革兰氏阳性菌血液分离株的杀菌活性比较
Clin Microbiol Infect. 2008 Feb;14(2):124-9. doi: 10.1111/j.1469-0691.2007.01888.x. Epub 2007 Dec 10.
8
In vitro activity of teicoplanin against gram-positive cocci.替考拉宁对革兰氏阳性球菌的体外活性。
Pathol Biol (Paris). 2000 Oct;48(8):792-5.
9
10
Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.一项关于革兰氏阳性临床分离株对替考拉宁和万古霉素的比较敏感性的欧洲合作研究的临床相关性。
Int J Antimicrob Agents. 1998 Nov;10(4):271-7. doi: 10.1016/s0924-8579(98)00050-8.
引用本文的文献
1
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.雷莫拉宁、替考拉宁、万古霉素、利奈唑胺、杆菌肽及其他四种抗菌药物对肠道厌氧菌的体外活性
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8. doi: 10.1128/AAC.47.7.2334-2338.2003.
2
Current perspectives on glycopeptide resistance.糖肽类耐药性的当前观点
Clin Microbiol Rev. 1995 Oct;8(4):585-615. doi: 10.1128/CMR.8.4.585.
3
In vitro activity of fluoroquinolones against gram-positive bacteria.氟喹诺酮类药物对革兰氏阳性菌的体外活性。
Drugs. 1995;49 Suppl 2:48-57. doi: 10.2165/00003495-199500492-00009.
4
Activity of teicoplanin and vancomycin against penicillin-resistant pneumococci.替考拉宁和万古霉素对耐青霉素肺炎球菌的活性。
Eur J Clin Microbiol Infect Dis. 1994 Jan;13(1):1-2. doi: 10.1007/BF02026115.
5
Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of ramoplanin MICs.用于测定雷莫拉宁最低抑菌浓度（MIC）的琼脂稀释法、试管稀释法和肉汤微量稀释法药敏试验的比较。
J Clin Microbiol. 1994 May;32(5):1364-5. doi: 10.1128/jcm.32.5.1364-1365.1994.
6
Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis.用甲氧苄啶-磺胺甲恶唑和抑制细胞壁合成的抗生素治疗由甲氧西林敏感或耐甲氧西林金黄色葡萄球菌引起的实验性心内膜炎。
Antimicrob Agents Chemother. 1995 Apr;39(4):953-7. doi: 10.1128/AAC.39.4.953.
本文引用的文献
1
Vancomycin toxicity: a prospective study.
J Antimicrob Chemother. 1985 Jun;15(6):773-80. doi: 10.1093/jac/15.6.773.
2
In vitro evaluation of ramoplanin (MDL 62198, A 16686).瑞莫拉宁（MDL 62198，A 16686）的体外评估
Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):819-21. doi: 10.1007/BF01975062.
3
4
Vancomycin-resistant enterococci.耐万古霉素肠球菌
Lancet. 1988;1(8575-6):57-8. doi: 10.1016/s0140-6736(88)91037-9.
5
Mild nephrotoxicity associated with vancomycin use.与使用万古霉素相关的轻度肾毒性。
Arch Intern Med. 1989 Aug;149(8):1777-81.
6
Vancomycin- and erythromycin-induced hearing loss in humans.万古霉素和红霉素所致的人类听力损失
Antimicrob Agents Chemother. 1989 Jun;33(6):791-6. doi: 10.1128/AAC.33.6.791.
7
Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.万古霉素、替考拉宁、雷莫拉宁（原A16686）、帕地霉素、DuP 721和DuP 105对耐甲氧西林和耐庆大霉素金黄色葡萄球菌的体外活性比较
J Antimicrob Chemother. 1989 Apr;23(4):517-25. doi: 10.1093/jac/23.4.517.
8
In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.瑞莫拉宁（A16686或MDL62198）的体外评估。一种潜在可用于局部给药的新型缩酚酸肽复合物。
Diagn Microbiol Infect Dis. 1989 May-Jun;12(3):279-82. doi: 10.1016/0732-8893(89)90029-1.
9
Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species.耐万古霉素的明串珠菌属、片球菌属和乳杆菌属菌种的抗菌药敏性
Antimicrob Agents Chemother. 1990 Apr;34(4):543-9. doi: 10.1128/AAC.34.4.543.
10
Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.1980 - 1989年美国医院原发性血流感染的长期趋势。国家医院感染监测系统。
Am J Med. 1991 Sep 16;91(3B):86S-89S. doi: 10.1016/0002-9343(91)90349-3.
Zotero 插件